Background: Vitamin B12 deficiency, a common cause of megaloblastic anemia, has been associated with cognitive decline and increasing risk of depression. Metformin therapy has been associated with vitamin B12 (B12) deficiency in several populations. However, information regarding this adverse effect in Argentina populations is limited. The aim of this study was to examine the relation between metformin use and B12 status in individuals with type 2 diabetes mellitus (T2DM) in Argentina.

Design and Setting: Cross-sectional study at a public university hospital.

Results: At present 190 patients were included (See Table 1). Serum vitamin B12 levels were low (< 200 ngl/mL) in 28 patients (14.7%) and borderline (200-300 ng/ml in 48 patients (25.26 %). Only one patient showed laboratory findings consistent with anemia megaloblastic.

Conclusions and Future Directions: Our study showed low or borderline levels of vitamin B12 in 14.7.3% and 25.26 % of patients, respectively. This large number of patients with low o borderline levels of B12 suggests that a high proportion of patients may be at risk of B12 deficiency related conditions. Close monitoring of B12 level, and measurement of other biomarkers of cellular B12 deficiency may help to identify these patients at risk.


C. Cela: None. M. Langus: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at